Study | DIPOL | AVID | RESIST | TULIP | OPTICUS | Total | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
IVUS | QCA | IVUS | QCA | IVUS | QCA | IVUS | QCA | IVUS | QCA | IVUS | QCA | |
Patients, n | 83 | 80 | 369 | 375 | 79 | 76 | 73 | 71 | 273 | 275 | 877 | 877 |
Death, n (%) | 1 (1.2) | 1 (1.3) | 12 (3.3) | 7 (1.9) | 1 (1.3) | 1 (1.3) | 2 (2.7) | 1 (1.4) | 5 (1.8) | 1 (0.36) | 21 (2.4) | 11 (1.3) |
Nonfatal MI, n (%) | 1 (1.2) | 4 (5) | 25 (6.8) | 19 (5.1) | N/A | N/A | 1 (1.4) | 5 (7.0) | 6 (2.2) | 10 (3.6) | 33 (4.1) 1 | 38 (4.7) 1 |
MACE, n (%) | 6 (7.2) | 13 (16.2) | 68 (18.4) | 70 (18.7) | 20 (25.3) | 28 (36.8) | 9 (12.3) | 19 (26.8) | 49 (17.9) | 42 (15.3) | 152 (17.3) | 172 (19.6) |